• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Our Bureau

HYDERABAD, May 20

SUVEN Life Sciences USA LLC, a wholly-owned subsidiary set up recently by the Hyderabad-based Suven Pharmaceuticals Ltd (SPL), has acquired the assets of the New Jersey-based Synthon Chiragenics Corporation, the global leader in carbohydrate-based chiral technology for pharmaceuticals.

Announcing this here on Tuesday, SPL said Synthon Chiragenics Corp was the first and only company to unlock the rich source of chirality contained in naturally occurring carbohydrates, using its proprietary technology to economically construct the most challenging chiral molecules, which serve as cores for drugs being developed in the fast-growing therapeutic areas such as anti-virals, antibiotics and anti-cancers.

This assumes significance since it was considered a key step for SPL in its ambition to emerge as a leading full spectrum provider of discovery related services by 2005.

Commenting on the acquisition of Synthon Chiragenics' assets, the company said: "This acquisition will cut time to market the services and offers a significant boost to Suven's chances of bagging R&D projects."

According to SPL, demand for a wide range of services such as clinical trials, contract research and manufacturing and a host of other areas was set to show explosive growth post-2005.

Citing the recent reports of PricewaterhouseCoopers and Ernst & Young, the company said the opportunity was estimated in the range of $20-billion.

Through a focussed approach adopted since 1995, Suven Pharma has emerged as one of the key players in custom synthesis for new chemical entities (NCEs).

Its strong relationships with over 20 leading global life science companies around the world in the past nine years enabled it attain a strategic competitive advantage as the competition picked up from other Indian companies.

At present, SPL has a base of 100 scientists in its R&D wing, which was expected to grow significantly in the medium term.

The company expects the US development centre and marketing front-end - Suven Life Sciences LLC USA - to be fully operational by the year-end and play a vital role in winning new R&D projects.

According to the company, the US subsidiary would employ four to six doctoral candidates in addition to a small scientific and technical staff.

The company is of the view that existence of this front-end outfit would enhance exposure of its R&D capabilities in the most lucrative North American market and also pave the way for transition from pre-clinical level development to final manufacturing.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Three injured in RSP mishap; probe ordered

Copyright © 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line